ClinicalTrials.gg
CompletedNCT04102007Updated Nov 27, 2023Results posted

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

A Phase 3 interventional study of Risankizumab in Plaque Psoriasis, sponsored by AbbVie. Completed at 57 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-27.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
9th of 30
244 · median 162
Started
2019
with 2 others
Phase 3
17 of 30
none open now
Registered
18th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 9th largest by enrollment, is one of 3 that started in 2019, is one of 17 in phase 3, and was the 18th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from switching to risankizumab with regard to skin symptoms, quality of life symptoms and psoriasis symptoms.

Study duration will last for up to 64 weeks with risankizumab given by subcutaneous injection at Week 0, Week 4, and then every 12 weeks for 52 Weeks (With the last dose being administered at Week 40). An additional visit will occur at Week 8 for a physical exam and questionnaire collection. A final follow-up phone call will occur at Week 60.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Plaque Psoriasis Risankizumab Secukinumab Ixekizumab Psoriasis Biologic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with moderate to severe chronic plaque psoriasis for at least 6 months before Baseline (Week 0).
  • Participant must have been on labeled secukinumab or ixekizumab treatment for at least 6 months and are experiencing suboptimal response at time of Screening and Baseline visits.
  • Participant must have a Body Surface Area (BSA) 3%- \<10% and Static Physician Global Assessment (sPGA) 2/3
  • Participant must be eligible for continued biologic therapy as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • History of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis, psoriatic arthritis.
  • Participant with active skin disease other than plaque psoriasis that could interfere with the assessment of plaque psoriasis.
  • History of any documented active or suspected or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.
  • History of major surgery within 12 weeks prior to Baseline or planned to be performed during the conduct of the trial as assessed by the investigator.
  • Participant with exposure to risankizumab or any IL-23 inhibitors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Other
    Risankizumab

    Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab

    Drug: Risankizumab

Interventions

  • Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).

    Also known as: SKYRIZI

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1

    The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

    Time frame: At Week 16

Secondary outcomes

  1. Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)

    The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

    Time frame: At Week 16

  2. Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1

    The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.

    Time frame: At Week 16

  3. Proportion of Participants Achieving a Psoriasis Symptoms Scale (PSS) 0

    The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).

    Time frame: At Week 16

  4. Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1

    The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

    Time frame: At Week 52

  5. Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)

    The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

    Time frame: At Week 52

  6. Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1

    The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.

    Time frame: At Week 52

  7. Proportion of Participants Achieving a PSS 0

    The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).

    Time frame: At Week 52

  8. Time to Achieve sPGA 0/1

    The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

    Time frame: Up to Week 52

  9. Time to Achieve sPGA 0

    The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

    Time frame: Up to Week 52

07

Results

Posted Mar 21, 2023

Participant flow

Significant site non-compliance for this study was identified at one site since interim results were posted. As a result of this finding, participants enrolled in this trial site were not included in any final analysis. Adverse events or lab abnormalities were reported in 1 participant from this site. The participant was on risankizumab and had a non serious event of headache (assessed as mild), which did not lead to study drug discontinuation

Participant flow — Overall Study
MilestoneRisankizumab
Started244
Completed205
Not completed39
Withdrew: Adverse event4
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject12
Withdrew: Eligibility violation5
Withdrew: Lack of efficacy6
Withdrew: Protocol deviation5
Withdrew: Protocol compliance1
Withdrew: Withdrew treatment2
Withdrew: Pregnancy1

Outcome measures

PrimaryProportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1

The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1
ParticipantsRisankizumab
Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1140
Statistical analysis
  • Risankizumab · Other · Proportion of spga 0/1 @ wk 16: 57.4 · 95% CI 51.1 to 63.4Non-Responder Imputation incorporating multiple imputation to handle missing due to COVID-19 for proportion calculation and Wilson score method for confidence interval construction
SecondaryProportion of Participants Achieving a sPGA Clear Response (sPGA 0)

The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)
ParticipantsRisankizumab
Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)50
Statistical analysis
  • Risankizumab · Other · Proportion of spga 0 @ wk 16: 20.5 · 95% CI 15.4 to 26.0Non-Responder Imputation incorporating multiple imputation to handle missing due to COVID-19 for proportion calculation and Wilson score method for confidence interval construction
SecondaryProportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1

The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1
ParticipantsRisankizumab
Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/198
Statistical analysis
  • Risankizumab · Other · Proportion of dlqi 0 or 1 @ wk 16: 40.2 · 95% CI 34.2 to 46.4Non-Responder Imputation incorporating multiple imputation to handle missing due to COVID-19 for proportion calculation and Wilson score method for confidence interval construction
SecondaryProportion of Participants Achieving a Psoriasis Symptoms Scale (PSS) 0

The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Proportion of Participants Achieving a Psoriasis Symptoms Scale (PSS) 0
ParticipantsRisankizumab
Proportion of Participants Achieving a Psoriasis Symptoms Scale (PSS) 051
Statistical analysis
  • Risankizumab · Other · Proportion of pss 0 @ wk 16: 20.9 · 95% CI 16.3 to 26.4Non-Responder Imputation incorporating multiple imputation to handle missing due to COVID-19 for proportion calculation and Wilson score method for confidence interval construction
SecondaryProportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1

The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1
ParticipantsRisankizumab
Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1152
Statistical analysis
  • Risankizumab · Other · Proportion of spga 0/1 @ wk 52: 62.3 · 95% CI 56.0 to 68.1Non-Responder Imputation incorporating multiple imputation to handle missing due to COVID-19 for proportion calculation and Wilson score method for confidence interval construction
SecondaryProportion of Participants Achieving a sPGA Clear Response (sPGA 0)

The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)
ParticipantsRisankizumab
Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)66
Statistical analysis
  • Risankizumab · Other · Proportion of spga 0 @ wk 52: 27.1 · 95% CI 21.9 to 33.0Non-Responder Imputation incorporating multiple imputation to handle missing due to COVID-19 for proportion calculation and Wilson score method for confidence interval construction
SecondaryProportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1

The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1
ParticipantsRisankizumab
Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1115
Statistical analysis
  • Risankizumab · Other · Proportion of dlqi 0 or 1 @ wk 52: 47.2 · 95% CI 41.0 to 53.4Non-Responder Imputation incorporating multiple imputation to handle missing due to COVID-19 for proportion calculation and Wilson score method for confidence interval construction
SecondaryProportion of Participants Achieving a PSS 0

The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving a PSS 0
ParticipantsRisankizumab
Proportion of Participants Achieving a PSS 067
Statistical analysis
  • Risankizumab · Other · Proportion of pss 0 @ wk 52: 27.5 · 95% CI 22.3 to 33.4Non-Responder Imputation incorporating multiple imputation to handle missing due to COVID-19 for proportion calculation and Wilson score method for confidence interval construction
SecondaryTime to Achieve sPGA 0/1

The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

Time frame:
Up to Week 52
Reported as:
Number · Days
Time to Achieve sPGA 0/1
DaysRisankizumab
25th30 (29 to 38)
Median57 (57 to 110)
75th199 (134 to 282)
SecondaryTime to Achieve sPGA 0

The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.

Time frame:
Up to Week 52
Reported as:
Number · Days
Time to Achieve sPGA 0
DaysRisankizumab
25th121 (113 to 201)
Median370 (366 to NA)
75thNA (NA to NA)

Adverse events

Collected over From Baseline Day 1 up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risankizumab0/244 (0%)17/244 (7%)31/244 (12.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventRisankizumab
MYOCARDIAL INFARCTIONCardiac disorders2/244
OSTEOARTHRITISMusculoskeletal and connective tissue disorders2/244
CORONARY ARTERY DISEASECardiac disorders1/244
LARGE INTESTINAL HAEMORRHAGEGastrointestinal disorders1/244
OEDEMATOUS PANCREATITISGastrointestinal disorders1/244
OESOPHAGEAL VARICES HAEMORRHAGEGastrointestinal disorders1/244
CHOLELITHIASISHepatobiliary disorders1/244
APPENDICITISInfections and infestations1/244
DIVERTICULITISInfections and infestations1/244
POSTOPERATIVE WOUND INFECTIONInfections and infestations1/244
Most frequent other events
Most frequent other events
EventRisankizumab
COVID-19Infections and infestations21/244
NASOPHARYNGITISInfections and infestations14/244

Baseline characteristics

Age, Continuous
Age, Continuous(years)Risankizumab
Mean49.2 ± 12.81
Age, Customized
Age, Customized(Participants)Risankizumab
< 40 years65
40 - 65 years150
≥ 65 years29
Sex: Female, Male
Sex: Female, Male(Participants)Risankizumab
Female63
Male181
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Risankizumab
Hispanic or Latino17
Not Hispanic or Latino227
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Risankizumab
American Indian or Alaska Native1
Asian27
Native Hawaiian or Other Pacific Islander0
Black or African American1
White214
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Risankizumab
United States64
Germany65
Italy27
Spain17
United Kingdom12
Israel34
Australia3
Taiwan22
08

Study locations

57 sites
  • Alliance Dermatology and MOHs /ID# 216001
    Phoenix, Arizona 85032, United States
  • Burke Pharmaceutical Research /ID# 225023
    Hot Springs, Arkansas 71913-6404, United States
  • Arkansas Research Trials /ID# 225497
    North Little Rock, Arkansas 72117, United States
  • Bakersfield Derma & Skin Cance /ID# 213480
    Bakersfield, California 93309, United States
  • UC Davis Health /ID# 225367
    Sacramento, California 95816-3300, United States
  • CCD Research, PLLC /ID# 216062
    Cromwell, Connecticut 06416-1745, United States
  • Florida International Rsrch cr /ID# 224983
    Miami, Florida 33173, United States
  • Advanced Medical Research /ID# 213484
    Sandy Springs, Georgia 30328-6141, United States
  • Arlington Dermatology /ID# 216000
    Rolling Meadows, Illinois 60008, United States
  • Dawes Fretzin, LLC /ID# 216004
    Indianapolis, Indiana 46256, United States
  • DermAssociates-Rockville /ID# 213837
    Rockville, Maryland 20850, United States
  • Cleaver Dermatology /ID# 226137
    Kirksville, Missouri 63501-5362, United States
  • Central Dermatology, PC /ID# 213479
    Saint Louis, Missouri 63117, United States
  • University Hospitals Case Medical Center /ID# 214795
    Cleveland, Ohio 44106, United States
  • University of Pittsburgh MC /ID# 225644
    Pittsburgh, Pennsylvania 15260, United States
  • Clinical Partners, LLC /ID# 213836
    Johnston, Rhode Island 02919, United States
  • Arlington Research Center, Inc /ID# 215526
    Arlington, Texas 76011, United States
  • Bellaire Dermatology /ID# 225486
    Bellaire, Texas 77401, United States
  • Modern Research Associates, PL /ID# 213835
    Dallas, Texas 75231, United States
  • Menter Dermatology Res Inst /ID# 214002
    Dallas, Texas 75246, United States
  • St George Dermatology & Skin Cancer Centre /ID# 213888
    Kogarah, New South Wales 2217, Australia
  • Veracity Clinical Research /ID# 213889
    Woolloongabba, Queensland 4102, Australia
  • Skin Health Institute Inc /ID# 213886
    Carlton, Victoria 3053, Australia
  • Fremantle Dermatology /ID# 213887
    Fremantle, Western Australia 6160, Australia
  • Universitaetsklinikum Erlangen /ID# 214228
    Erlangen, Bayern 91054, Germany
  • Universitaetsklinikum Frankfurt /ID# 215889
    Frankfurt am Main, Hessen 60590, Germany
  • Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 215691
    Berlin, 10117, Germany
  • Klinikum Ruhr Univ Bochum /ID# 225473
    Bochum, 44791, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 214469
    Luebeck, 23538, Germany
  • Dermatologische Gemeinschaftspraxis Mahlow /ID# 225472
    Mahlow, 15831, Germany
  • Beldio Research GmbH /ID# 225471
    Memmingen, 87700, Germany
  • Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 214506
    Munich, 81675, Germany
  • The Chaim Sheba Medical Center /ID# 213815
    Ramat Gan, Tel-Aviv 5265601, Israel
  • Tel Aviv Sourasky Medical Center /ID# 213812
    Tel Aviv-Yafo, Tel-Aviv 6423906, Israel
  • HaEmek Medical Center /ID# 214059
    Afula, 1834111, Israel
  • Rabin Medical Center /ID# 213813
    Petakh Tikva, 4941492, Israel
  • Istituto Clinico Humanitas /ID# 214749
    Rozzano, Milano 20089, Italy
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 214745
    Bologna, 40138, Italy
  • Azienda Ospedaliero Universitaria di Cagliari- Presidio Ospedaliero /ID# 214748
    Cagliari, 09124, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 214750
    Milan, 20122, Italy
  • Azienda Ospedaliero-Universitaria di Modena /ID# 214751
    Modena, 41124, Italy
  • AOU Universita degli Studi della Campania Luigi Vanvitelli /ID# 214752
    Napoli, 80138, Italy
  • Hospital Universitario Germans Trias i Pujol /ID# 214031
    Badalona, Barcelona 08916, Spain
  • Hospital Universitario Fundacion Alcorcon /ID# 214033
    Alcorcon, Madrid 28922, Spain
  • Hospital Parc de Salut del Mar /ID# 214034
    Barcelona, 08003, Spain
  • Hospital Puerta del Mar /ID# 214428
    Cadiz, 11009, Spain
  • Hospital Universitario La Paz /ID# 214341
    Madrid, 28046, Spain
  • Hospital Universitario y Politecnico La Fe /ID# 214032
    Valencia, 46026, Spain
  • Chung Shan Medical University Hospital /ID# 213634
    Taichung, 40201, Taiwan
  • National Taiwan University Hospital /ID# 213630
    Taipei City, 100, Taiwan
  • MacKay Memorial Hospital /ID# 213845
    Taipei City, 10449, Taiwan
  • Linkou Chang Gung Memorial Hospital /ID# 213631
    Taoyuan City, 333, Taiwan
  • Victoria Hospital /ID# 213881
    Kirkcaldy, Fife KY2 5AH, United Kingdom
  • Russells Hall Hospital, Dudley /ID# 213878
    Dudley, DY1 2HQ, United Kingdom
  • Leeds Teaching Hospitals NHS Trust /ID# 213880
    Leeds, LS9 7TF, United Kingdom
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 213877
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • Northern Care Alliance NHS Group /ID# 213873
    Salford, M6 8HD, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvieclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jan 2022, 26 months.

Results were first posted in Mar 2023, 1 year 2 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 26 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 25, 2019
StartActual
Nov 12, 2019
Primary completionActual
Jan 17, 2022
CompletionActual
Nov 7, 2022
Results first posted
Mar 21, 2023
Last update
Nov 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04102007
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Nov 12, 2019
Primary completion
Jan 17, 2022
Completion
Nov 7, 2022
Results posted
Mar 21, 2023
Last update
Nov 27, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion